Delivery Order SPE2DB20D1100-SPE2DB25FE3Z5
- Not listed
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $4,343.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 29, 2025, with completion targeted for July 30, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,491.03 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets (30-count units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 22, 2025. The contract represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government, with performance taking place at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This $9,372.07 firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by August 28, 2025. The contract is executed under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December...
- The Defense Logistics Agency awarded a $2,513.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) with an ultimate completion date of August 25, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of XELJANZ 5 MG with a ceiling value of $34,967.46 under a firm fixed price contract. This is a non-set-aside competitive award, with performance through August 19, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is a child contract issued under...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE3Z5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies totaling $2,252.09 on September 2, 2025, with completion expected by September 3, 2025. The order is for XELJANZ 5 MG tablets in quantities of 60 units and will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This is a firm fixed-price delivery order issued with no set-aside designation, indicating it was awarded through competitive procurement processes. The award represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen is a major pharmaceutical distributor and healthcare solutions provider that supplies a wide spectrum of pharmaceutical products, medical devices, and specialized healthcare commodities to federal military and veteran healthcare systems. The XELJANZ delivery supports the company's ongoing role as a critical vendor in the federal medical supply chain, fulfilling pharmaceutical procurement needs across multiple therapeutic domains for defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/2/25 |